• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sponsors Report Trial Adjustments During Pandemic

Sponsors Report Trial Adjustments During Pandemic

April 13, 2020

A number of research efforts reported disruptions last week to their trial efforts due to the COVID-19 pandemic:

  • San Francisco, Calif.-biotech firm Denali Therapeutics has paused recruitment of additional patients at higher doses in two trials for Parkinson’s disease. It also halted recruitment for a Hunter syndrome trial due to the national health emergency. The company said “considerable uncertainty remains” about how other trials will be affected going forward.
  • Cancer Research UK has had to cut $54.8 million (£44 million) of research funding in response to the outbreak. The oncology research charity predicts a drop in income of up to 25 percent in 2020. It added that it has had to furlough at least 40 percent of its workforce.
  • Cell-based medicine developer MaxCyte said that its life sciences business may be impacted by the virus, noting that some clinical sites could be restricted solely to COVID-19 research. It also said that its commissioned clinical trials may face delays.
  • Immuno-oncology company Trillium Therapeutics expects new patient enrollment to slow down — potentially to a halt — for two dose-escalation studies. The studies target CD47, a “do not eat” protein cancer cells can use to evade the body’s immune system.
  • Protease inhibitor developer KalVista Pharmaceuticals’ phase 2 trial for hereditary angioedema is likely to experience a delay in reporting of data. The company said that it expects to have results to present in the second half of 2020.
  • Certain components of Swedish biotech company Cantargia’s development program for a systemic sclerosis and myocarditis antibody have been affected, including biochemistry and production, forcing it to move the start date of the phase 1 trial to early 2022.
  • Inventiva has suspended the recruitment and screening of new patients in its phase 2 trial of lanifibranor for treating non-alcoholic fatty liver disease for all of its University of Florida sites.
  • Neurotology therapeutic developer Otonomy has had three trials impacted by the pandemic. Enrollment for its phase 3 trial for Ménière’s disease and phase 1/2 tinnitus trial is being handled on a site-by-site basis according to local conditions, while its phase 1/2 trial for hearing loss has seen enrollment temporarily paused.
COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing